Bexotegrast is a small molecule commercialized by Pliant Therapeutics, with a leading Phase III program in Idiopathic Pulmonary Fibrosis. According to Globaldata, it is involved in 11 clinical trials, of which 8 were completed, 2 are ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Bexotegrast’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Bexotegrast is expected to reach an annual total of $21 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Bexotegrast Overview
Bexotegrast (PLN-74809) is under development for the treatment of primary sclerosing cholangitis, idiopathic pulmonary fibrosis (IPF), liver fibrosis and COVID-19-related acute respiratory distress syndrome. The drug candidate acts by targeting integrin alpha 5 beta 6 and integrin alpha 5 beta 1.
Pliant Therapeutics Overview
Pliant Therapeutics is a clinical-stage biopharmaceutical company that primarily focuses on the development of treatments for fibrotic diseases. The company’s pipeline products include PLN-74809, idiopathic pulmonary fibrosis (IPF); PLN-101095, primary sclerosing cholangitis (PSC); PLN-101325 and PLN-1474. Pliant Therapeutics‘ products are primarily targeted towards patients suffering from fibrotic diseases and related conditions. Its therapies are designed to inhibit integrin-mediated activation of transforming growth factor beta (TGF-ß), a key driver in fibrosis. Pliant Therapeutics is headquartered in South San Francisco, California, the US.
The company reported revenues of (US Dollars) US$1.6 million for the fiscal year ended December 2023 (FY2023), a decrease of 83.7% over FY2022. The operating loss of the company was US$184.2 million in FY2023, compared to an operating loss of US$127.2 million in FY2022. The net loss of the company was US$161.3 million in FY2023, compared to a net loss of US$123.3 million in FY2022.
For a complete picture of Bexotegrast’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
